Early in the epidemic, it was well recognised that the best long-
term hopes for controlling AIDS is the development and widespread
distribution of a safe, effective and affordable vaccine, which
prevents primary infections. Over the last 10 years, funding for HIV
vaccine research has grown astronomically. The 2006 funding for AIDS vaccine development neared the US$1 billion mark, coming in at an estimated US$949 million. This figure reflects a 25 percent increase from 2005. The funders in the field have been The International AIDS Vaccine Initiative (IAVI), Bill & Melinda Gates Foundation, NIH, Europrise. Other players in the field include the Center for HIV- AIDS Vaccine Immunology (CHAVI) and the Gates-funded Collaboration for AIDS Vaccine Discovery (CAVD) which unite major players in the field with unique agreements on data- and sample-sharing, all with the goal of overcoming some of the toughest scientific challenges. For more about the HIV vaccine research field and community related work, visit www.avac.org and read the AVAC Report 2007: Re-Setting the Clock. In the HIV vaccine field there has been one completed phase III trial in Thailand. The product was found not to be able to provide enough protection from HIV infection. Recently, another HIV vaccine trial (Step and Phambili studies which were testing Merck’s candidate) was stopped because data from the studies were not showing any promises of the vaccine providing protection for trial participants. There are other HIV vaccine candidates been tested around the world including India, China and South Africa While there is advancement with HIV Vaccine research and development, there is also equal efforts at developing a safe,
effective and affordable microbicides which will allow women – who
most bear the brunt of the epidemic – power to protect themselves
from infection. There types of candidate microbicide that went
through phase III trials (trials that involve 1000s of persons to
test of the product or drug can do what it is expected to do when
used in conditions less than ideal) – Nonoxynol 9, SAVVY, Cellulose
sulphate – were not found to be effective. Results of the Carraguard
studies, another candidate microbicide that underwent phase III
trials in South Africa, would be out in February 2008. We still
await results of the Pro 2000 and Pro2000/Buffer gel studies. We
should hopefully have these by 2008. There are also a lot of new
studies at phase I (studies to show products are safe) and phase II
(studies to show products can do what they are meant to do under
ideal conditions). These new studies are evaluating antiretrovirals
as possible microbicides.

In an effort to ensure that HIV prevention is comprehensive (read
attached slides), many studies are been undertaken to develop more prevention strategies. These include:

• The possible use of antiretrovirals to prevent HIV infection. This
is known as HIV pre exposure prophylaxis. The concept is borrowed
from other pre-exposure prohylaxis like malaria and TB prophylaxis
where the same drugs used for treatment can be used to prevent
infection
• Adult male circumcision which three large scales studies have
shown to help reduce the incidence of HIV infection
• Cervical barriers. However recent studies using the diaphragm
shows that this does not reduce the risk for HIV infection
• Herpes Simplex virus infection treatment
• Evaluation of newer HIV treatment drugs so as to ensure effective
HIV infection management and reduce the rate of transmission of
infection. Currently, 3 new antiretrovirals have been approved for
use by the FDA in the USA.

Any questions?
Moderator